MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, ALDX had -$5,038,949 decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$5,038,949
Unit: Dollar
Positive Cash Flow Breakdown
    • Prepaid expenses and other curre...
    • Proceeds from exercise of stock ...
    • Depreciation and amortization ex...
    • Non-cash interest expense
Negative Cash Flow Breakdown
    • Net loss
    • Accrued expenses and other liabi...
    • Stock-based compensation
    • Accounts payable

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-3,452,619 -6,461,507 -7,688,341 -19,696,813
Stock-based compensation
-987,554 1,090,081 2,580,754 2,420,578
Non-cash interest expense
50,368 50,367 50,368 117,525
Net amortization of premium on marketable securities
0 44,075 266,560 838,915
Depreciation and amortization expense
66,599 65,116 63,683 123,194
Write-off of deferred offering costs
0 0 0 267,261
Prepaid expenses and other current assets
-470,688 -420,494 -50,152 -708,358
Accounts payable
-17,105 145,038 -1,016,107 849,077
Accrued expenses and other liabilities
-1,240,466 -564,859 -795,365 -4,975,186
Net cash used in operating activities
-5,110,089 -5,299,345 -7,021,416 -21,024,921
Purchases of marketable securities
0 0 0 40,263,712
Maturities of marketable securities
0 16,000,000 25,000,000 47,000,000
Net cash provided by investing activities
0 16,000,000 25,000,000 6,736,288
Proceeds from issuance of common stock, net of issuance costs
--0 -
Issuance costs
-0 --
Proceeds from exercise of stock options
71,140 0 120,746 983,194
Proceeds from employee stock purchase plan
0 0 0 19,616
Debt end of term charge paid in cash
-0 --
Net cash provided by financing activities
71,140 0 120,746 1,002,810
Net decrease in cash and cash equivalents
-5,038,949 10,700,655 18,099,330 -13,285,823
Cash and cash equivalents, beginning of period
70,041,254 59,340,599 54,527,092 -
Cash and cash equivalents, end of period
65,002,305 70,041,254 59,340,599 -
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from exercise ofstock options$71,140 Net cash provided byfinancing activities$71,140 Net decrease in cashand cash...-$5,038,949 Canceled cashflow$71,140 Prepaid expenses andother current assets-$470,688 Depreciation andamortization expense$66,599 Non-cash interestexpense$50,368 Net cash used inoperating activities-$5,110,089 Canceled cashflow$587,655 Net loss-$3,452,619 Accrued expenses andother liabilities-$1,240,466 Stock-based compensation-$987,554 Accounts payable-$17,105

Aldeyra Therapeutics, Inc. (ALDX)

Aldeyra Therapeutics, Inc. (ALDX)